TIRZEPATIDE WEIGHT LOSS CLINIC FOR CHRONIC WEIGHT ISSUES
Lose Up to 10% of Your Body Fat in 12-24 Weeks
- Reduce appetite
- Regulate blood sugar
- Only one treatment per week
![](https://thrivehydraspa.com/wp-content/uploads/2024/06/tirz-2-1024x853.webp)
PRE-TIRZEPATIDE USAGE
Before embarking on Tirzepatide treatment, it’s essential to address important aspects to ensure optimal results and safety. Before using Tirzepatide, consider the following:
TIRZEPATIDE ADMINISTRATION GUIDE
Tirzepatide is a weight loss injection solution provided in the form of an injectable. This allows patients to administer the medication into their stomachs, thighs, or the back of their upper arms. Before injecting, it is important to choose an appropriate injection site. For weight loss purposes, Tirzepatide typically requires weekly injections.
BENEFITS OF TIRZEPATIDE TREATMENT
Achieving weight loss can have significant positive impacts on your overall health and well-being.
- Improved Glycemic Control
- Weight Loss Promotion
- Cardiovascular Health Improvement
- Sustained Benefits
- HbA1c Reduction
- Enhanced Overall Health
HOW SHOULD TIRZEPATIDE BE STORED?
Tirzepatide should be stored in a refrigerator within the temperature range of 36°F to 46°F (2°C to 8°C). Safeguard the medication from light by keeping it in its original carton until use. In the case of single-dose pens, they can be stored at room temperature for a period of 21 days, if necessary. It is crucial to strictly adhere to the recommended storage instructions provided. Familiarize yourself with the proper storage guidelines to ensure the medication remains effective and potent.
WHO IS A GOOD CANDIDATE FOR TIRZEPATIDE?
You might be eligible for receiving tirzepatide treatment if you have:
- Excess Weight
- High Cholesterol
- High Blood Pressure
- Health Complications
- BMI More Than 30
- Type-2 Diabetes
ADVERSE REACTIONS
Tirzepatide usage can lead to certain undesirable effects such as:
- Tirzepatide may cause initial side effects related to digestion, including diarrhea, nausea, vomiting, stomach pain, constipation, and decreased appetite.
- It is important to be vigilant for potential allergic reactions, thyroid cancer, gallbladder issues, and low blood sugar while using Tirzepatide.
- Monitor your symptoms closely and promptly inform our office, we may need to adjust your dosage based on your individual response to the medication. If Symptoms persists we will manage accordingly.
TIMELINE FOR EXPECTED RESULT
Consultation with our healthcare professional is important to determine the right approach for your specific needs.
Tirzepatide injections can lower blood glucose levels immediately. It may take 8 to 12 weeks to start noticing weight loss results.
Compared to Semaglutide, Tirzepatide users may achieve their target weight four weeks sooner.
On average, significant weight loss is observed after 28 weeks of Tirzepatide use. Individual physiology, body type, and medical history can influence the timeframe for results.
WHO SHOULD AVOID USING TIRZEPATIDE?
Tirzepatide, while beneficial for weight loss in overweight patients, may not be suitable for everyone. Individuals with pre-existing conditions such as pancreatitis, kidney problems, diabetic retinopathy, gastroparesis, or medullary thyroid cancer should exercise caution. Pregnant or breastfeeding women should also avoid using Tirzepatide due to potential harm to the fetus or negative effects on newborns through breast milk. Consulting with healthcare provider is essential in determining the appropriateness of Tirzepatide for obesity treatment. It is crucial to disclose your complete medical history, including any recent life changes, to ensure the safety and effectiveness of the treatment. By working closely with healthcare professionals, patients can make informed decisions about their weight loss journey and receive the most suitable and beneficial care.
TIRZEPATIDE VS SEMAGLUTIDE
In a recent trial, different doses of tirzepatide (5 mg, 10 mg, and 15 mg) were compared to a 1 mg dose of semaglutide in patients with type 2 diabetes on metformin. Tirzepatide outperformed semaglutide in reducing glycated hemoglobin levels and achieving target levels recommended by diabetes associations.
Additionally, tirzepatide resulted in greater weight loss compared to semaglutide, with the 15 mg dose showing the most significant effect. These findings highlight tirzepatide’s potential as a superior treatment option for improving glycemic control and promoting weight reduction in patients with type 2 diabetes.